Bayer teams with Cenix in RNAi tech discovery deal
Bayer has inked a deal with preclinical CRO Cenix BioScience to use its genome-scale RNA interference (RNAi) platform to target an undisclosed disease.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs